Golimumab (Simponi IV — Janssen Inc.) indication: rheumatoid arthritis
CADTH
Record ID 32015000179
English
Authors' recommendations:
The Canadian Drug Expert Committee (CDEC) recommends that intravenous (IV) golimumab be listed for use in combination with methotrexate (MTX) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), if conditions are met.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/media/cdr/complete/SR0351_complete_Simponi_IV_Jul-21-14.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antirheumatic Agents
- Treatment Outcome
- Drug Evaluation
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- Drug Therapy, Combination
- Disease Progression
- Canada
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.